The prognostic value of bone marrow involvement at the molecular level in aggressive lymphoma

Neta Goldschmidt*, Fares Darawshy, Geffen Kleinstern, Elena Slyusarevsky, Galina Pogrebijski, Svetlana Krichevsky, Dina Ben-Yehuda, Moshe E. Gatt

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

2 Scopus citations


We retrospectively studied the prognostic role of molecular (gene rearrangement, GRR) bone marrow (BM) involvement in diffuse large B-cell lymphoma (DLBCL, 424 patients) and in peripheral T-cell lymphoma (PTCL, 67 patients). When correlating BM GRR to histological findings at diagnosis, the GRR test was more sensitive (p = 0.036) but less specific (p < 0.0001) in PTCL than in DLBCL. For DLBCL (but not PTCL), a positive BM GRR correlated with advanced stage (p = 0.0001) and high IPI (p = 0.002), and worsened the progression free survival (PFS) (p = 0.05) and overall survival (OS) (p = 0.01), irrespective of rituximab treatment. Histologic negative/GRR positive cases had worse PFS/OS (p < 0.0001) than histologic/GRR double negative cases, however BM GRR was not an independent prognostic survival factor. End-of-treatment BM GRR did not predict survival. We conclude that BM GRR is unjustified as a prognostic tool for PTCL and should be reserved for a subset of DLBCL patients with negative histology of the BM.

Original languageAmerican English
Pages (from-to)45-52
Number of pages8
JournalLeukemia and Lymphoma
Issue number1
StatePublished - 2 Jan 2017
Externally publishedYes

Bibliographical note

Publisher Copyright:
© 2016 Informa UK Limited, trading as Taylor & Francis Group.


  • Gene rearrangement
  • bone marrow
  • diffuse large B-cell lymphoma
  • peripheral T-cell lymphoma


Dive into the research topics of 'The prognostic value of bone marrow involvement at the molecular level in aggressive lymphoma'. Together they form a unique fingerprint.

Cite this